Capricor Therapeutics (CAPR) recently drew investor attention after presenting Phase 3 HOPE-3 data for Deramiocel in Duchenne muscular dystrophy at the 2026 American Academy of Neurology meeting, alongside an ongoing Biologics License Application review.

The latest HOPE-3 data and ongoing BLA review have arrived alongside strong momentum, with a 30 day share price return of 17.96%, a 90 day share price return of 52.03% and a very large 3 year total shareholder return. This suggests that recent news is feeding into both shorter term enthusiasm and a much longer run up in the stock.

If you are weighing Capricor’s prospects against other health related growth ideas, it could be worth scanning for opportunities in 33 healthcare AI stocks

With Capricor trading at US$35.27, showing an intrinsic discount and sitting well below the average analyst price target, the key question is whether the market still underestimates Deramiocel’s potential or already prices in future growth.

Most Popular Narrative: 30.6% Undervalued

Against the last close at $35.27, the most followed narrative points to a fair value of about $50.80, framing Capricor as materially undervalued based on modeled future cash flows.

Capricor's strong cash position ($122.8M), combined with the potential to receive a priority review voucher and an $80M milestone payment upon approval, provides a cushion to minimize dilution risk and support commercial launch, which may positively impact future earnings per share and reduce financing overhang.

Curious what kind of growth curve and margin shift are baked into that higher fair value, and how rich a future earnings multiple the narrative leans on?

Result: Fair Value of $50.80 (UNDERVALUED)

However, the story still hinges heavily on Deramiocel clearing regulatory hurdles on schedule, while rising R&D spend and ongoing losses keep dilution risk firmly in play.

Next Steps

The mix of enthusiasm and caution around Capricor will not mean much unless you test the numbers yourself and decide what feels reasonable. To weigh both sides of the story and pressure test your own view, start by reviewing the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Capricor has your attention, do not stop here. Broaden your watchlist now so you are not relying on a single story.

• Spot potential value plays early by scanning a focused list of 56 high quality undervalued stocks before attention fully shifts to them.
• Prioritize resilience by checking companies in the 72 resilient stocks with low risk scores that pair lower risk scores with more robust fundamentals.
• Hunt for underfollowed opportunities by reviewing the screener containing 24 high quality undiscovered gems that may not yet be widely discussed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.